ClinicalTrials.gg
Not yet recruitingNCT07503093Updated Oct 5, 2026

Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis

An interventional study of Smartphone-based Mindfulness Exercise and Smartphone-based Psychoeducation in Psychosis, Anxiety and Depression, sponsored by Mclean Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.

Planned enrollment
15th of 17
10 · median 50
Started
2027
the only one that year
No phase
11 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one is the 15th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 11 with no phase, and was the 18th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psychotic Disorders by Mclean Hospital, or all of them as a file.
02

Study summary

The aim of this trial is to evaluate the feasibility and preliminary efficacy of using passive smartphone sensors to detect moments of heightened negative mood and inform the timing of brief mental health interventions, such as mindfulness exercises and psychoeducation, in adults with early psychosis.

Read the detailed description

Negative mood symptoms are highly prevalent in early psychosis and strongly linked to long-term functional impairment and risk of relapse. Smartphone-based interventions offer a scalable and accessible solution for delivering personalized mental health support in daily life.

The goal of this micro randomized trial (MRT) is to evaluate the feasibility of using passive smartphone sensor data and machine learning to identify optimal moments for delivering smartphone app-based brief mental health interventions such as mindfulness exercises and psychoeducation, specifically moments when individuals are both most in need of support and most receptive to it.

The primary aim of this pilot study is to assess the feasibility and acceptability of the MRT study design, including recruitment and retention rates, EMA adherence, and participant feedback gathered through qualitative exit interviews to inform future design improvements. A secondary aim is to evaluate the feasibility of training an idiographic machine learning model using passive smartphone sensor data to detect moments of heightened negative affect. An exploratory aim is to estimate preliminary intervention effect sizes to inform a future fully powered clinical trial and to identify contextual factors associated with participant engagement.

03

Conditions studied

  • Psychosis
  • Anxiety
  • Depression
  • Rumination

Keywords

  • Mirco-Randomized Study
  • Mobile Health
  • Psychosis
  • Digital Mental Health
  • Negative Mood
  • Digital Phenotyping
  • Passive Sensors
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-50 years
  • History of psychotic disorder (e.g., schizophrenia, schizoaffective disorder, psychosis not otherwise specified)
  • Current elevated mood symptoms, defined as mild or greater depressive symptoms (Patient Health Questionnaire-8 score ≥5) or anxiety symptoms (Generalized Anxiety Disorder-7 score ≥5)
  • Own a personal iPhone or Android smartphone
  • Willing and able to provide
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Active suicidal ideation with both intent and a specific plan.
  • Current substance use disorder requiring acute treatment
  • Diagnosis of neurodevelopmental disorder that would impair ability to use smartphone app or complete study procedures
  • Traumatic brain injury with significant cognitive impairment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Within-Person Micro-randomization

    Each participant is randomized four times per day to receive one of four conditions with equal probability (33.3% each): a mindfulness exercise, psychoeducation, a neutral control message. A brief EMA is completed before and after each randomization event to measure proximal changes in mood (sadness, anxiety, irritability, stress, rumination).

    Behavioral: Smartphone-based Mindfulness Exercise · Behavioral: Smartphone-based Psychoeducation · Behavioral: Neutral Control Message

Interventions

  • BehavioralSmartphone-based Mindfulness Exercise

    A brief approximately 1 minute video guided mindfulness based breathing exercise designed to anchor attention to the present moment and reduce negative affect in the moment by guiding participants through a structured breathing technique.

  • BehavioralSmartphone-based Psychoeducation

    A brief text or video based psychoeducation message delivered via the smartphone app. Content covers the nature of emotions and emotion regulation strategies, aimed at improving emotional awareness and coping skills in the moment.

  • BehavioralNeutral Control Message

    A brief text or video based message containing random facts delivered via the MetricWire smartphone app. This serves as an active control condition to allow comparison with the active intervention conditions.

06

What researchers measure

Primary outcomes

  1. Retention Rate

    Proportion of enrolled participants who completed the full 10 week study protocol, including both Phase 1 and Phase 2.

    Time frame: 10 weeks

  2. EMA Completion Rate

    Proportion of ecological momentary assessment (EMA) prompts answered by participants out of the total number delivered during Phase 1 and Phase 2.

    Time frame: 10 weeks

  3. Participant Acceptability and Satisfaction

    Participant acceptability and satisfaction with the study app and intervention content, assessed through a structured qualitative exit interview and feedback questionnaire at the end of the study.

    Time frame: Week 10

Secondary outcomes

  1. Proximal Change in Negative Affect

    Change in self reported negative affect from pre to post intervention phone-based ecological momentary assessment at each randomization event during the micro-randomized trial. Negative affect is assessed using a visual analog scale (0 to 100) measuring sadness, anxiousness, irritability, and rumination. Active intervention conditions (mindfulness and psychoeducation) are compared to neutral control conditions to generate preliminary effect size estimates.

    Time frame: 4 weeks

  2. Patient Health Questionnaire-8 (PHQ-8)

    All participants complete the Patient Health Questionnaire-8 (PHQ-8), an 8-item self-report measure of depressive symptom severity, at the start and at the end of the study. Each item is rated on a scale of 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 24. Higher scores indicate greater depressive symptom burden.

    Time frame: 4 weeks

  3. Generalized Anxiety Disorder-7 (GAD-7)

    All participants complete the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report measure of anxiety symptom severity, at the start and at the end of the study. Each item is rated on a scale of 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21. Higher scores indicate greater anxiety symptom burdens.

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — This is a small pilot feasibility study with a sample size of 10 participants. Individual participant data will not be shared given the limited sample size, the exploratory and preliminary nature of the study, and the sensitive nature of the data collected. In particular, the study collects passive smartphone sensor data including GPS location data, which is inherently poses potential privacy risks. Findings from this pilot will inform the design of a future fully powered trial, at which point a formal data sharing plan will be developed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2027, 3 months later.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 3 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartEst.
Jan 15, 2027was Aug 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Jan 15, 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date Aug 1, 2026→Jan 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07503093
Lead sponsor
Mclean Hospital
Responsible party
Yoonho Chung (Principal Investigator, Mclean Hospital) — Principal investigator
First posted
Mar 31, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Yoonho Chung, PhD
Contact
ychung3@mgb.org
617-855-2854
Justin T Baker, MD, PhD
Contact
jtbaker@mgb.org
617-855-3913

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion